AEGEAN Study - FDA Approval of Durvalumab in Resectable Non-Small Cell Lung Cancer

Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive into the recent approval of Durvalumab in the perioperative settings for non-small cell lung cancer, based on the AEGEAN trial.

Join us as we welcome Dr. Sandip Patel, a medical oncologist from UCSD, and Dr. Mara Antonoff, a thoracic surgeon from MD Anderson, to discuss the implications of this new treatment option. We explore the study design of the AEGEAN trial, its differences from other trials like Keynote 671, and the importance of a multidisciplinary approach in managing lung cancer patients.

Key topics include:
•⁠ ⁠Overview of the AGEAN trial and its findings
•⁠ ⁠The significance of neoadjuvant and adjuvant therapies
•⁠ ⁠The role of surgical evaluation and molecular profiling
•⁠ ⁠Insights on patient selection and treatment strategies

As we shift towards more perioperative and postoperative treatments, understanding the nuances of these approaches is crucial for optimizing patient outcomes. Tune in for valuable insights and discussions that can help shape your practice!

Don't forget to like, subscribe, and hit the notification bell for more episodes on recent approvals and practice-changing data in oncology!
#OncologyBrothers #LungCancer #Dervalumab #AEGEANTrial #MultidisciplinaryCare #MedicalOncology #thoracicsurgery